This program is intended for hematologists/oncologists and other multidisciplinary care team members who treat patients with AML.
This program aims to improve learners’ knowledge, confidence, and competence in integrating the latest clinical guidance and expert recommendations on the role of maintenance therapy in the long-term management of AML into clinal practice.
Upon completion of this activity, participants should be able to:
Characterize the AML patient profile identifying those at risk for early relapse and who may benefit from maintenance therapy
Select optimal maintenance strategies in AML based on the latest clinical evidence and expert guidance to improve patient outcomes
Implement evidence-based interventions to manage treatment-related adverse events
Formulate collaborative strategies and shared decision-making practices to ensure patient engagement in treatment decisions
Identify all patients, regardless of race, age, or gender, with AML who would likely benefit from treatment or enrollment on a clinical trial
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Eytan M. Stein, MD: consultant/advisor/speaker: AbbVie, Agios, Aptose, Astellas, Blueprint, Bristol Myers Squibb, Calithera, CTI Biopharma, Daiichi Sankyo, Foghorn, Genentech, Genesis, Gilead, Janssen, Jazz Pharmaceuticals, Kura, Menarini, Neoleukin, Novartis, OnCusp, Ono Pharma, PinotBio, Servier, Syndax, Syros; data and safety monitoring board: Cellectis, Epizyme; researcher: Bristol Myers Squibb, Eisai; stock/stock options: Auron.
Amir T. Fathi, MD: consultant/advisor/speaker: AbbVie, Agios, Amgen, Astellas, Autolus, Bristol Myers Squibb, Celgene, Enclear, Daiichi Sankyo, Forma, Genentech, Immunogen, Ipsen, Kite, Mablytics, Menarini, Novartis, Orum, Pfizer, PureTech, Remix, Rigel, Servier, Takeda.
Amer Zeidan, MBBS, MPH: researcher: AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cardiff Oncology, Celgene, Geron, Incyte, MedImmune, Novartis, Otsuka, Pfizer, Shattuck Labs, Takeda, Trovagene; consultant: AbbVie, Acceleron, Agios, ALX Oncology, Amgen, Aprea, Astellas, BeyondSpring, BioCryst, Bristol Myers Squibb, Boehringer Ingelheim, Cardiff Oncology, Cardinal Health, Celgene, Chiesi, Daiichi Sankyo, Epizyme, Foran, Genentech, Geron, Gilead, Incyte, Ionis, Janssen, Jazz, Kura, Mendus, Notable, Novartis, Orum, Otsuka, Pfizer, Seattle Genetics, Servier, Syndax, Syros, Taiho, Takeda, Trovagene, Tyme.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 21, 2023, through June 20, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
The program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.